Quantifying and Predicting the Promiscuity and Isoform Specificity of Small-Molecule Cytochrome P450 Inhibitors

Drug promiscuity (i.e., inhibition of multiple enzymes by a single compound) is increasingly recognized as an important pharmacological consideration in the drug development process. However, systematic studies of functional or physicochemical characteristics that correlate with drug promiscuity are handicapped by the lack of a good way of quantifying promiscuity. In this article, we present a new entropy-based index of drug promiscuity. We apply this index to two high-throughput data sets describing inhibition of cytochrome P450 isoforms by small-molecule drugs and drug candidates, and we demonstrate how drug promiscuity or specificity can be quantified. For these drug-metabolizing enzymes, we find that there is essentially no correlation between a drug's potency and specificity. We also present an index to quantify the susceptibilities of different enzymes to inhibition by diverse substrates. Finally, we use partial least-squares regression to successfully predict isoform specificity and promiscuity of small molecules, using a set of fingerprint-based descriptors.

[1]  J. Peters,et al.  Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.

[2]  Eric Jones,et al.  SciPy: Open Source Scientific Tools for Python , 2001 .

[3]  L. Cohen,et al.  Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  Caroline A. Lee,et al.  Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. , 2008, Journal of pharmacological and toxicological methods.

[5]  Mudita Singhal,et al.  Machine learning based prediction for peptide drift times in ion mobility spectrometry , 2010, Bioinform..

[6]  J. O’Shea,et al.  Selectivity and therapeutic inhibition of kinases: to be or not to be? , 2009, Nature Immunology.

[7]  Ruili Huang,et al.  Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries , 2009, Nature Biotechnology.

[8]  Dustin J Maly,et al.  Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Kristin E. D. Coan,et al.  Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.

[10]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[11]  G. Ubeaud‐Séquier,et al.  The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals , 2008, Clinical pharmacokinetics.

[12]  W. Atkins Implications of the allosteric kinetics of cytochrome P450s. , 2004, Drug discovery today.

[13]  L. Buydens,et al.  Visualisation and interpretation of Support Vector Regression models. , 2007, Analytica chimica acta.

[14]  D. Greenblatt,et al.  Clinical Studies of Drug–Drug Interactions: Design and Interpretation , 2010 .

[15]  Principal Component Analysis of CYP2C9 and CYP3A4 Probe Substrate/Inhibitor Panels , 2008, Drug Metabolism and Disposition.

[16]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[17]  Sang Joon Kim,et al.  A Mathematical Theory of Communication , 2006 .

[18]  M. J. Coon,et al.  Cytochrome P450: nature's most versatile biological catalyst. , 2005, Annual review of pharmacology and toxicology.

[19]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[20]  Sean Ekins,et al.  Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. , 2010, Chemical research in toxicology.

[21]  Thomas Lengauer,et al.  Ensemble Methods for Classification in Cheminformatics , 2004, J. Chem. Inf. Model..

[22]  M. Monshouwer,et al.  Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase. , 2008, Chemical research in toxicology.

[23]  Chad L. Stoner,et al.  In Silico Approaches to Predict DDIs , 2010 .

[24]  E. Jaynes Information Theory and Statistical Mechanics , 1957 .

[25]  B. Shoichet Screening in a spirit haunted world. , 2006, Drug discovery today.

[26]  Rieko Arimoto,et al.  Development of CYP3A4 Inhibition Models: Comparisons of Machine-Learning Techniques and Molecular Descriptors , 2005, Journal of biomolecular screening.

[27]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[28]  H. Abdi Partial Least Squares (PLS) Regression. , 2003 .

[29]  W. Atkins,et al.  A quantitative index of substrate promiscuity. , 2008, Biochemistry.